Drug Trial Radar · NCT05883748
HELIOS: Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Efficacy of DISC-1459 (Bitopertin) in Participants With EPP or XLP
Last checked: Nov 19, 2026Latest source record: Oct 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Enrolling by invitation
Enrollment
230
Planned (sponsor's estimate)
Start
Aug 31, 2023
Primary completion
Jun 2028
Study completion Jun 2028
Sponsor
- Lead sponsor
- Disc Medicine, IncIndustry
- Sponsor type
- Industry
- First posted
- Jun 1, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, long-term extension study to investigate the safety, tolerability and efficacy of DISC-1459 in participants with EPP.
Conditions
- Erythropoietic Protoporphyria
Interventions
DISC-1459Drug
DISC-1459 dose level 1
DISC-1459Drug
DISC-1459 dose level 2
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of treatment-emergent adverse eventsTime frame: up to 5 Years
- Incidence of clinically abnormal vital signsTime frame: up to 5 Years
- Incidence of clinically abnormal physical examTime frame: up to 5 Years
- Incidence of abnormal laboratory test resultsTime frame: up to 5 Years
- Assessment of Patient Health Questionnaire (PHQ-8)Time frame: up to 5 Years
- Assessment of C-SSRSTime frame: up to 5 Years
Locations
26 sites in 11 countries. Site status is shown where the registry gives one.
University of Alabama Hospital
Birmingham, Alabama
University of California San Francisco
San Francisco, California
University of Miami Miller School of Medicine
Miami, Florida
Massachusetts General Hospital
Boston, Massachusetts
MetroBoston Clinical Partners
Boston, Massachusetts
Mount Sinai Hospital
New York, New York
Atrium Health Wake Forest Baptist
Winston-Salem, North Carolina
Remington-Davis Clinical Research
Columbus, Ohio
Einstein Medical Center
Philadelphia, Pennsylvania
University of Texas
Galveston, Texas
Fred Hutchinson Cancer Center
Seattle, Washington
Royal Prince Alfred Hospital
Camperdown, New South Wales, Australia
The Royal Melbourne Hospital
Parkville, Victoria, Australia
UZ Leuven
Leuven, Belgium
CHU de Nantes - Hôtel Dieu, Service de dermatologie
Nantes, France, France
Centre d'Investigation Clinique (CIC) Hôpital Bichat - Claude-Bernard
Paris, France, France
Charité - Universitätsmedizin Berlin, Institute of Allergology
Berlin, Germany, Germany
Klinikum Chemnitz gGmbH
Chemnitz, Saxony, Germany
Children's Health Ireland (CHI)
Dublin, Ireland
Instituto Dermatologico San Gallicano Istituti Fisioterapici Ospitalieri IRCCS
Roma, Italy
Erasmus MC
Rotterdam, Netherlands
Hospital Clinic de Barcelona
Barcelona, Spain, Spain
Karolinska University Hospital
Stockholm, Sweden, Sweden
Photobiology Unit, Salford Royal Hospital
Salford, United Kingdom
Guy's and St Thomas' NHS Foundation Trust
London, England, United Kingdom
Clinical Research Centre, Ninewells Hospital & Medical School , NHS Tayside
Dundee, Scotland, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.